Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933 is registered in ClinicalTrials.gov with Hoth Therapeutics, Inc. as lead sponsor.

NCT NCT05639933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05639933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Lead sponsor
Hoth Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 19, 2023
Completion date
December 30, 2026
Enrollment
152 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acneiform eruption due to chemical, paronychia, xerosis cutis